Abstract
We designed this randomized controlled trial (RCT) to assess whether lobaplatin-based concurrent chemotherapy might be superior to cisplatin-based concurrent chemotherapy for FIGO stage II and III cervical cancer in terms of efficacy and safety. This prospective, open-label RCT aims to enroll 180 patients with FIGO stage II and III cervical cancer, randomly allocated to one of the three treatment groups (cisplatin 15mg/m2, cisplatin 20mg/m2 and lobaplatin 35mg/m2), with 60 patients in each group. All patients will receive external beam irradiation (EBRT) and high-dose-rate intracavitary brachytherapy (HDR-ICBT). Patients in cisplatin 15mg/m2 and 20mg/m2 groups will be administered four cycles of 15mg/m2 or 20mg/m2 cisplatin intravenously once weekly from the second week to the fifth week during EBRT, while patients inthe lobaplatin 35mg/m2 group will be administered two cycles of 35mg/m2 lobaplatin intravenously in the second and fifth week respectively during pelvic EBRT. All participants will be followed up for at least 12 months. Complete remission rate and progression-free survival (PFS) will be the primary endpoints. Overall survival (OS), incidence of adverse events (AEs), and quality of life will be the secondary endpoin...Continue Reading
References
Jun 29, 1995·Biochemical Pharmacology·A G EliopoulosD A Spandidos
Jan 1, 1993·Cancer Chemotherapy and Pharmacology·A HarstrickH J Schmoll
Jan 1, 1995·Investigational New Drugs·M DegardinH Roché
May 20, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C W WhitneyS Y Liao
Dec 16, 2000·Expert Opinion on Investigational Drugs·M J McKeage
Jul 24, 2001·Medical and Pediatric Oncology·Y Tsuchida, P Therasse
Nov 27, 2007·International Journal of Radiation Oncology, Biology, Physics·William SmallArno J Mundt
Jan 24, 2008·Nature Clinical Practice. Neurology·Richard Hughes
Feb 9, 2012·Anti-cancer Drugs·Jörg B EngelArnd Honig
Mar 24, 2012·Anti-cancer Drugs·Cheng-Ying XieLi-Guang Lou
Mar 29, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Qian-Qian DengJin Xiang
Jun 4, 2013·Asian Pacific Journal of Cancer Prevention : APJCP·Xin-En HuangJi-Feng Feng
Nov 19, 2013·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Xiaoqin LiDonghong Wang
Feb 27, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Nan WangJia-Rui Li
Apr 11, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Chang ZhaoChun-Peng Yu
Citations
Dec 4, 2015·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Furui ZhangGuoqiang Zhao
Feb 28, 2018·Nature Communications·Xiujuan WuYi Zhang
Apr 17, 2019·Oncology Letters·Ying ChengHao Yu
Feb 17, 2017·BMC Cancer·Liang-Ru KeXing Lv
Jun 21, 2016·Journal of Materials Chemistry. B, Materials for Biology and Medicine·Di ZhouYang Sun
Mar 30, 2019·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Jingchao He, Haijun Zhang
Mar 30, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Shupei PanXiaozhi Zhang